SAN FRANCISCO, Oct. 16 /PRNewswire/ -- Genstar Capital, LLC, a middle market private equity firm that focuses on investments in selected segments of life sciences and healthcare services, industrial technology, business services and software, today announced that it has formed a strategic relationship with David A. Dodd to accelerate Genstar's investment efforts in life sciences.
Mr. Dodd, former CEO of Serologicals Corporation and a 30-year veteran of the specialty pharmaceuticals and life sciences industries, will work jointly with Harold W. "Bud" Ingalls, who has worked with Mr. Dodd as Chief Financial Officer, to source investment opportunities in these growing industry sectors.
Mr. Dodd entered the pharmaceutical industry in 1977 and built the foundation of his pharmaceutical experience at Abbott Laboratories, McDonnell- Douglas Healthcare Systems, and Bristol-Myers Squibb. Most recently, from 2000 to 2006, he was President and CEO of Serologicals Corporation, a publicly traded company that was sold to Millipore Corporation in 2006 for $1.4 billion after he successfully led the transformation of that company. From 1995 to 2000 he served as President and CEO of Solvay Pharmaceuticals, a subsidiary of the Solvay Group. Prior to that he was with Wyeth-Ayerst Laboratories, Inc. where he headed U.S. Pharmaceuticals during his five-year tenure. Mr. Dodd entered general management with Mead Johnson Laboratories, the women's healthcare division of Bristol-Myers Squibb.
"David has been enormously successful in large global pharmaceutical companies as well as in smaller, more dynamic life science organizations," said Robert J. Weltman, Managing Director of Genstar Capital. "He has a reputation for transforming underperforming businesses and making them into more profitable enterprises with strong and growing market share. David and Bud have worked closely together and share a strong network of other senior executives and valuable industry contacts throughout the world of life sciences which will help us identify attractive investment opportunities and to transform those companies into strong businesses."
Speaking of their new relationship with Genstar, Mr. Dodd, said, "Bud and I are very pleased to be associated with Genstar which has an excellent reputation for building outstanding companies in the healthcare and life sciences fields. Working with Genstar provides a strong platform to target investment opportunities and create growing companies."
Mr. Ingalls most recently served as CFO of CardioMEMS, Inc., an early stage medical device company. Prior to that he served as Vice President- Finance and CFO of Serologicals for five years. From 1996 to 2001 he was with LaRoche Industries, Inc., an international diversified commodity and specialty chemical manufacturer, serving as President and CEO from 1998 to 2001. Early in his career he joined Waste Management, Inc. where he worked in several financial executive positions at the company and its divisions.
Genstar works closely with leading industry executives who are current or former leaders of major corporations whose knowledge and expertise span many industries. They serve as unique resources and provide valuable tools to portfolio company management teams to help them succeed. The firm has most recently added Operating Partners and senior executives to its Strategic Advisory Board (SAB) from companies including, Kaiser Aluminum Corporation, Altra Industrial Motion, Inc., Siebel Systems, Wild Oats Markets, Inc., and ICOS Corporation. The SAB also includes executives from Pharmacia & Upjohn, Inc., CNA Insurance Companies, Deere & Co., Axia Health Management, MedImmune, Inc., WellPoint, Inc., Barnes Group, and NEN Life Science Products.
About Genstar Capital, LLC
Based in San Francisco, Genstar Capital (www.gencap.com) is a private equity investment firm that makes leveraged investments in quality middle- market companies. Genstar Capital works in partnership with management to transform its portfolio companies into industry-leading businesses. With more than $3 billion of committed capital under management and significant experience investing in businesses, Genstar focuses on selected segments of life science and healthcare services, industrial technology, business services and software services.
CONTACT: Chris Tofalli for Genstar Capital, LLC, +1-914-834-4334
Web site: http://www.gencap.com/
